Clinical Trials Logo

Hyperplasia clinical trials

View clinical trials related to Hyperplasia.

Filter by:

NCT ID: NCT02697175 Completed - Clinical trials for Uterine Cervical Dysplasia

Video Colposcopy in Women With Dysplasia

Start date: August 2016
Phase: N/A
Study type: Interventional

To assess the effect of live video-colposcopy on women´s anxiety.

NCT ID: NCT02681471 Completed - Acute Hyponatremia Clinical Trials

Bipolar Versus Monopolar Resection of Benign Prostate Hyperplasia

Start date: December 2013
Phase: N/A
Study type: Interventional

Aim of this prospective clinical study was to compare two different surgical techniques and used solutions on serum electrolytes, bleeding and Transurethral Resection of Prostate (TURP) syndrome undergoing TURP. Fifty-three patients scheduled for elective TURP were enrolled in this prospective clinical study. Patients were included one of two groups (Group Monopolar and Group Bipolar).

NCT ID: NCT02667938 Completed - Clinical trials for Benign Prostatic Hyperplasia

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules

Start date: March 2015
Phase: Phase 3
Study type: Interventional

The main objective of this study is to evaluate efficacy and safety of HCP1301 capsule in patients with Benign Prostatic Hyperplasia and Erectile Dysfunction

NCT ID: NCT02645890 Completed - Clinical trials for Benign Prostatic Hyperplasia

Study to Compare the Safety and Pharmacokinetics of CKD-397

CKD-397
Start date: November 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare the safety and pharmacokinetics profiles of CKD-397 in healthy male volunteers.

NCT ID: NCT02639442 Completed - Clinical trials for Benign ProstaticHyperplasia (BPH)

Clinical Study for the Evaluation of the Safety and Initial Performance of the ClearRing System for the Treatment of Benign Prostatic Hyperplasia

Start date: December 2015
Phase: N/A
Study type: Interventional

The ProArc Medical ClearRing™ system is a prostatic reshaping device that is designed to treat Lower Urinary Tract Symptoms (LUTS) due to BPH. During the procedure an implant is delivered into the prostate tissue obstructing the urethra and restricting urine flow. The delivery system uses an electro-cutting blade to perform a circular and superficial incision, in which the implant is placed. Such an implant, with the shape of an open ring, expands the obstructed area, reducing the fluid obstruction through the prostatic urethra.

NCT ID: NCT02637960 Completed - Nocturia Clinical Trials

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)

EQUINOC
Start date: March 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This study will investigate the efficacy and safety of fedovapagon in the treatment of nocturia in men with BPH.

NCT ID: NCT02634489 Completed - Healthy Clinical Trials

EC905 Pharmacokinetic Profile Study

Start date: March 2009
Phase: Phase 1
Study type: Interventional

A study to compare the pharmacokinetics of tamsulosin HCl and solifenacin succinate after co-administration of single entity tablets and of the combination tablet EC905 under steady state conditions at three dose strengths.

NCT ID: NCT02625545 Completed - Clinical trials for Benign Prostatic Hyperplasia (BPH)

Study of Median Lobe Prostatic UroLift Procedure

Start date: February 17, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of using UroLift in subjects with a prostatic median lobe enlargement due to benign prostatic hyperplasia (BPH).

NCT ID: NCT02620696 Completed - Dyspepsia Clinical Trials

Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin

Start date: November 2009
Phase: Phase 1
Study type: Interventional

Hypergastrinaemia induced by proton pump inhibitor (PPI) treatment is reported to cause ECL-cell and parietal-cell hyperplasia, and rebound hyperacidity and dyspepsia after PPI withdrawal. The objective of the study was to determine the dosage regimen of netazepide, a gastrin/CCK2 receptor antagonist, required to inhibit the trophic effects of PPI-induced hypergastrinaemia. Six groups of 8 healthy subjects participated in a randomised, double-blind, placebo-controlled exploratory study of esomeprazole 40 mg daily for 28 days, and netazepide 1, 5 or 25 mg, or placebo daily during the last 14 days of esomeprazole dosing, or 14 days after esomeprazole withdrawal. Serum gastrin and plasma chromogranin A (CgA) were measured regularly from study start until at least 1 week after the last dose. Dyspepsia was monitored after esomeprazole withdrawal.

NCT ID: NCT02605759 Completed - Clinical trials for Esophageal Squamous Cell Dysplasia

Coldplay Cryoablation of Dysplastic Squamous Tissue in Patients With Esophageal Squamous Cell Dysplasia

Start date: March 2016
Phase: N/A
Study type: Interventional

To demonstrate the feasibility, safety and efficacy of the CryoBalloon Ablation System for the treatment of esophageal squamous cell dysplasia.